Kera Capital Partners
FDMT icon

Kera Capital Partners’s 4D Molecular Therapeutics FDMT Stock Holding History

Kera Capital Partners’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$315K Hold
24,068
– – 0.03% 537
2026
Q2 		$320K Hold
24,068
– – 0.03% 460
2026
Q1 		$224K Hold
24,068
– – 0.03% 513
2025
Q4 		$213K Hold
24,068
– – 0.03% 515
2025
Q3 		$209K Hold
24,068
– – 0.03% 395
2025
Q2 		$89.3K Buy
+24,068
New +$84.6K 0.02% 344

Other funds holding FDMT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Kera Capital Partners's FDMT Position: Q3 2026 in Review

Kera Capital Partners held its 4D Molecular Therapeutics (FDMT) position steady in Q3 2026 at 24,068 shares worth $315K. The position accounts for 0.03% of the portfolio, ranked #537.

Kera Capital Partners first reported a position in FDMT in Q2 2025 and has held it in 6 quarters since. The position peaked at $320K in Q2 2026. 110 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

  • Kera Capital Partners held 24,068 shares of 4D Molecular Therapeutics worth $315K as of Q3 2026.
  • Kera Capital Partners left its 4D Molecular Therapeutics share count unchanged in Q3 2026.
  • 4D Molecular Therapeutics made up 0.03% of Kera Capital Partners's portfolio in Q3 2026, its #537 holding.
  • Kera Capital Partners first reported a position in 4D Molecular Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Kera Capital Partners's 4D Molecular Therapeutics position peaked at $320K in Q2 2026.
  • 110 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on Kera Capital Partners's 13F filing for Q3 2026, filed 13 Nov 2026.